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resumo
Objetivos: estudar a freqüência e especificidade de auto-anticorpos 
contra antígenos específicos e não específicos da esclera no soro de pa-
cientes com esclerite anterior não infecciosa. Métodos: foi realizado 
estudo prospectivo envolvendo 25 pacientes examinados no Setor de 
Córnea e Doenças Externas do Departamento de Oftalmologia da 
Unifesp-EPM e no Laboratório de Imuno-Reumatologia da Unifesp-
EPM, durante um ano. Os critérios de esclerite foram estabelecidos 
conforme a classificação de Watson e Hayreh (1976). Os critérios de 
exclusão foram as esclerites infecciosas. Todos os pacientes tiveram 
avaliações clínica e oftalmológica completas, incluindo exames labo-
ratoriais para afastar doenças infecciosas como a sífilis e a tuberculose. 
Os seguintes auto-anticorpos foram testados: fator reumatóide, anti-
corpos antinucleares, anticorpos anticardiolipina, ANCA (anticorpos 
anticitoplasmáticos de neutrófilos), anti-SS-A/Ro, anti-SS-B/La, 
anti-Sm, anti-DNA e anti-APF (anticorpos antifator perinuclear). 
Para a pesquisa de auto-anticorpos contra antígenos específicos da 
esclera, o soro dos pacientes foi submetido à técnica de imunofluo-
rescência indireta e Western-blot utilizando esclera humana obtida em 
banco de olhos, como substrato. Os soros de 25 pacientes hígidos 
foram utilizados como grupo controle nos testes imunológicos. 
Resultados: auto-anticorpos contra antígenos não específicos da 
esclera foram detectados: um paciente com fator reumatóide positivo, 
dois pacientes com fator antinúcleo positivos, dois pacientes com 
anticorpos anticardiolipina positivos e dois pacientes com anti-APF. 
Auto-anticorpos contra antígenos específicos da esclera pela técnica 
de imunofluorescência indireta e Western-blot foram detectados no 
soro de dois pacientes com esclerite. Os dois pacientes com auto-
anticorpos contra antígenos específicos da esclera não apresentavam 
auto-anticorpos contra antígenos não específicos da esclera nem 
tinham doença reumática auto-imune. Os controles normais foram 
aBstract
Objectives: to study the frequency and specificity of sclera-
specific and non-sclera-specific autoantibodies in the sera 
of patients with anterior non-infectious scleritis. Methods: 
prospective study involving 25 patients examined at the sec-
tor of Cornea and External Disease of the Department of 
Ophthalmology and Immuno-Rheumatology Laboratory at 
Federal University of São Paulo/Paulista Medicine School, 
during one year. The diagnosis of scleritis was according to 
Watson and Hayreh`s (1976) classification criteria. The exclu-
sion criterion was infectious scleritis. All the patients under-
went a full clinical and ophthalmologic evaluation, including 
serological tests for syphilis and tuberculosis investigation. 
The following autoantibodies were tested: rheumatoid fac-
tor, antinuclear antibodies, anticardiolipin antibodies, ANCA 
(anti-neutrophil cytoplasmic antibodies), anti-SS-A/Ro, 
anti-SS-B/La, anti-Sm, anti-DNA and anti-APF (antiperi-
nuclear factor). For sclera-specific autoantibodies, sera of all 
patients were subjected to indirect immunofluorescence and 
Western blot assays, using human sclera from eye banks as 
a substrate. Sera from 25 healthy individuals were used as a 
normal control in the immunologic assays. Results: as non-
sclera-specific autoantibodies we detected one patient with 
positive rheumatoid factor, two patients with positive anti-
nuclear antibodies, two patients with positive anticardiolipin 
antibody and two patients with positive anti-APF. Sclera-
specific autoantibodies were detected by Western blot and 
immunofluorescence in the serum of two patients with scleritis. 
The two patients with sclera-specific autoantibodies did not 
show non-sclera-specific autoantibodies and also presented no 
evidence of autoimmune rheumatic disease.  Normal controls 
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BackGrounD
Scleritis is an inflammatory disorder that may present as 
an isolated ophthalmic condition or as a manifestation of 
systemic conditions such as rheumatoid arthritis, systemic 
lupus erythematosus, vasculitis, and other autoimmune 
diseases (1-2). The exact pathophysiology of scleritis, ho-
wever, has not been yet totally elucidated. The etiologic 
diagnosis of scleritis remains a challenge in the clinical 
practice and is frequently not established. The abscence of 
a definite etiologic diagnosis often evokes the possibility 
of an autoimmune etiology and an immunosuppressive 
treatment is frequently empirically initiated. Although 
much research has been devoted to the relationship 
between scleritis and autoimmunity, the issue is far from 
being clarified (3). 
The detection of auto-antibodies and inflammatory 
mediators in the serum of patients with scleritis has been 
taken as evidence of the participation of the immune system. 
Antiphospholipid antibodies and increased serum levels 
of tumor necrosis factor (TNF) have been demonstrated 
in some patients with scleritis (4-6). Antibodies against 
54 kDa and 70 kDa epithelial proteins in sera of patients 
with corneal involvement in the context of rheumatoid 
arthritis and Wegener’s granulomatosis, respectively, have 
been identified (7). Similarly, patients with Mooren’s ulcer 
have been shown to carry serum antibodies against a 
protein called calgranulin (7 kDa) which is able to induce 
experimental autoimmune keratitis (8-9). 
Autoantigens with high probability of representing 
an immune stimulus capable of inducing scleritis should 
reside within the proteoglycan matrix (10). Putative changes 
in the proteoglycan lattice would expose novel epitopes 
during an ongoing non-specific inflammatory process, 
which would ultimately drive an autoimmune response. 
However, no specific autoantigen or autoantibody has 
been identified so far in the context of immune mediated 
scleritis (11).
oBjectives
To study the frequency and specificity of sclera-specific 
and non-sclera-specific autoantibodies in the serum of 
patients with anterior non-infectious scleritis. 
Patients anD methoDs
During a period of one year 25 patients over 18 years of 
age diagnosed as having anterior non-infectious acute scle-
ritis were consecutively selected from the External Eye and 
Corneal Diseases Outpatient Clinic at the Ophthalmology 
Department at Federal University of São Paulo – Brazil. 
All the patients signed a Consent Form approved by the 
Institution Ethics Committee. Patients underwent clinical, 
rheumatologic and ophthalmologic screening according 
to a specific protocol. Serological tests for syphilis (VDRL 
and FTA-ABS) and tuberculosis (TST- tuberculin skin test) 
were also done to exclude infectious scleritis. Scleritis was 
classified according to the criteria proposed by Watson et 
al.(11) into diffuse, nodular and necrotizing anterior scleritis. 
Peripheral ulcerative keratitis (PUK) was defined as the 
presence of corneal thinning with ulceration of surrounding 
cornea. Uveitis was diagnosed by the presence of one of the 
following: inflammatory cells in the anterior chamber, iris 
synechiae, endothelial keratic precipitates or fundoscopic 
changes (12,13).
Serum from patients was tested for antinuclear anti-
bodies (ANA) by indirect immunofluorescence technique 
(IIF) on HEp-2 cells (Hemagen, Whalton, MD)(14), 
rheumatoid factor (RF) by latex particle agglutination 
technique (15), anticardiolipin antibodies (IgM and IgG) by 
solid phase immunoenzymatic technique (16), anti-native 
DNA antibodies by IIF on Crithidia lucilae  (17), anti-Sm, 
anti-RNP, anti-SS-A/Ro and anti-SS-B/La antibodies 
by double immunodifusion technique against calf spleen 
extract (18), anti-neutrophil cytoplasm antibodies (c-ANCA 
and p-ANCA) by IIF (19) and antiperinuclear factor (APF) 
according to the  Hoet  method (20).
negativos para todos os auto-anticorpos testados. Conclusões: Auto-
anticorpos contra antígenos específicos da esclera foram detectados 
única e isoladamente no soro de pacientes com esclerite anterior não 
infecciosa. A presença de auto-anticorpos contra antígenos não espe-
cíficos da esclera foi observada em pacientes com doença reumática 
auto-imune e em pacientes com esclerite isolada. 
Palavras-chave: auto-anticorpos, esclerites, auto-imunidade, 
auto-antígenos.
were negative for all tested autoantibodies. Conclusions: 
Sclera-specific autoantibodies were detected solely in the se-
rum of patients with isolated non-infectious anterior scleritis. 
Non-sclera-specific autoantibodies were observed in patients 
with scleritis associated with autoimmune rheumatic disease 
and in patients with isolated scleritis. 
Keywords: autoantibodies, scleritis, autoimmunity, autoantigens.
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Sclera-specific autoantibodies were determined by in-
direct immunofluorescence and western blot using human 
sclera as substrate. For the indirect immunofluorescence 
assay, 4 µm-thick sclera cryosections mounted over regular 
glass slides were fixed with acetone at –20ºC for 10 minu-
tes. After incubation with patient’s serum diluted 1:20 in 
phosphate buffered saline pH 7.2 (PBS) for 30 minutes at 
37ºC, slides were thoroughly washed in PBS and incubated 
with fluorescein-labeled goat anti-human IgG (Fluolab, 
São Paulo, Brazil) for 25 minutes at room temperature. 
After washing for removal of buffer excess, slides were 
mounted with buffered glycerin and cover slips. Serum 
samples from 25 healthy controls were tested in parallel. 
Slides were analyzed under an Hg-powered fluorescence 
microscope (Olympus® BX 50) at x400 magnification and 
photmacrographs were obtained with an Olympus® PM-30 
camera. All analyses were carried out by two independent 
blinded investigators. 
For the Western blot assays fragments of sclera frozen 
at –120°C were grinded, resuspended into 1 mL PBS with 
and protease inhibitors (aprotinin 10 mg/mL, leupeptin 
10 mg/mL, EDTA 0.5 M and PMSF 10 mg/mL), and 
sonicated at grade 3 in a Branson® sonicator for 5 minutes. 
Samples were then homogenized by means of 10 strokes 
in a Douncer-type homogenizer. The homogenate was 
mixed volume to volume with 2x Laemmli buffer (SDS 
4,6 g, 2-mercaptoethanol 10 mL, glycerol 20 mL, bro-
mophenol blue 0.1% 2 mL, tris-HCL 12,5 mL, distilled 
water) and 1 mL guanidine 0,4 M buffer. The sclera extract 
was kept under constant agitation at 4ºC for a 12-hour 
period then kept at –80°C. Immediately before western 
blot the sclera extract was heated to 100ºC for about 5 
minutes and centrifuged for 10 minutes at 10,000g. The 
supernatant was subjected to electrophoresis in 12.5% 
SDS-polyacrilamide gel. After transferring to nitrocellu-
lose, 0.5cm-wide vertical strips were cut and soaked into 
blocking buffer (1% BSA 0.05% Tween 20 PBS) for 2 
hours at room temperature. Serum aliquots to be tested 
were diluted 1:20 into blocking buffer and incubated with 
individual nitrocellulose strips for 1 hour, under agitation, 
at room temperature. The nitrocellulose strips were then 
washed with washing buffer (0.05% Tween PBS) for 15 mi-
nutes three times under agitation, and incubated with goat 
anti-human gamaglobulin antibody conjugate to protein A 
(Amerchan-Bioscience®) diluted 1/1000 in blocking bu-
ffer for 30 minutes at room temperature. After washing as 
before, strips were incubated with carbonate-bicarbonate 
buffer pH 9.0 for 5 minutes. After removing buffer excess 
nitrocellulose strips were placed between two acetate sheets 
and luminol (ECL 750 I – Amerchan- Bioscience®) was 
placed over them to form a fluid film.  After 1 minute, the 
assembly was put into a light- proof cassette and exposed 
to radiographic film Kodak® (Kodak.S.P, Brazil) for 30 to 
50 seconds. The films were developed and fixed manually. 
Reading of the films was performed by two independent 
blinded observers. 
The positive control for the Western blot and IIF assays 
was monoclonal antibody against the extracellular protein 
laminine (Seikagaku® - Japan) diluted 1:4000. This mo-
noclonal antibody was expected to produce a band with 
an estimated molecular weight near 50kDa. In IIF, the 
monoclonal antibody yielded a high intensity staining with 
a peculiar lamellar pattern. As mentioned before, serum 
samples from 25 healthy volunteers were used as negative 
controls.  
results
Fifteen patients (60%) were over 51 years old, and ten 
patients (40%) were in the range between 20 and 50 years 
old. Twenty-two patients (88%) were female. Nineteen 
patients (76%) had unilateral and six patients (24%) bilateral 
scleritis. Thirteen patients (52%) had anterior nodular, 11 
patients (44%) had anterior diffuse, and one patient (4%) 
had anterior necrotizing scleritis. Seven patients (28%) had 
peripheral ulcerative keratitis, and two patients (8%) had 
anterior uveitis. Twenty-two patients (88%) did not have 
previous eye dysfunction, one patient (4%) underwent 
previous cataract surgery, one patient (4%) underwent 
previous pterygium surgery, and one patient (4%) had dry 
eye diagnosis. Twenty-two patients (88%) had no apparent 
systemic involvement, while two patients (8%) had systemic 
lupus erythematosus, and one patient (4%) had rheumatoid 
arthritis (RA). 
The frequency of non-sclera-specific antibodies was 
low in the study group: one patient (4%) presented rheu-
matoid factor at a 1:160 titer, two patients (8%) presented 
a positive ANA test with nuclear fine speckled pattern at 
1:320 and 1:80 titers, respectively, two patients (8%) pre-
sented low titer anticardiolipin antibodies (11 GPL and 
12 GPL, respectively) and two patients (8%) presented a 
positive antiperinuclear factor test at 1:320 and 1:80 titers, 
respectively.  
Clinical and immunological characteristics of non-sclera-
specific antibodies are showed in table I.
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Sclera-specific autoantibodies were also detected in low 
frequency. The serum of two patients presented a strong 
homogeneous lamellar staining pattern that was reproduci-
ble in repeated assays (Figure 1). The serum of these same 
patients recognized two bands with an estimated relative 
mobility of 40 kDa and 15 kDa, respectively (Figure 2). 
None of the other scleritis patients and healthy volunteers 
presented a relevant reactivity on IIF and Western blot. 
Clinical and immunological characteristics of sclera-
specific autoantibodies are showed in Table II.
Discussion
The present study reports for the first time the presence 
of sclera-specific autoantibodies in the serum of patients 
with non-infectious scleritis. These were observed in 
low frequency in the present sample. A low frequency of 
non-sclera-specific autoantibodies was also demonstrated. 
Patients with sclera-specific autoantibodies did not pre-
sent non-sclera-specific autoantibodies. The two patients 
with sclera-specific autoantibodies presented simultaneous 
reactivity in IIF and in Western blot, suggesting that the 
same autoantibody was detected in the two assays. This 
possibility needs to be tested by proceeding to an analysis 
of the IIF aspect of affinity-purified antibodies from the 
15kDa and 45kDa bands. 
The distribution of age and gender was characterized 
by a high prevalence of individuals above 50 years of age 
(60%) and a strong prevalence of women (88%), which is 
compatible with information available from the literature (11). 
The frequency of bilateral scleritis (24%) was less than that 
reported (8). These authors found bilateral scleral involvement 
table i 













Patient 3 ANA and APF – Anterior nodular -
Patient 4 RF – Anterior nodular -





Anterior    
difuse -
Patient 15 APF – Anterior    difuse -
Patient 22 ANA – Anterior    difuse
Systemic 
Lupus
Figure 1 – Indirect immunofluorescence in scleral tissue by using serum of patient 1: 
extra cellular matrix is stained in a homogeneous pattern. Magnification of x 400.
Figure 2 – Western blot using sclera whole extract as substrate: Molecular weight 
marker (GE Healthcare Bio-sciences®), monoclonal antibody against laminine 
(Seikagaku®- Japan) with 50 kDa band (positive control) and negative control 
(no bands visible). Reactivity against a 15 kDa and a 45 kDa band was observed 
with only two sera from patients with scleritis (patients 1 and 2).
table ii 
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in about 50% of their cases. The frequency of corneal invol-
vement in the present study (28%) was roughly equivalent 
to that observed by others (21).  
Although diffuse anterior scleritis is the most prevalent 
form reported in the literature (11), we found a higher fre-
quency of nodular anterior scleritis (52%).
Idiopathic scleritis, without association with systemic 
disease, was the most frequent presentation (88%), which 
is comparable to the findings of Watson et al. (2). However, 
it is known that several rheumatic systemic diseases may be 
associated with scleritis. The involvement of the eye, and 
particularly of the sclera, during the course of systemic rheu-
matic diseases is a consensus in the literature. In the present 
series, this was represented by systemic lupus erythematosus 
and rheumatoid arthritis in 12% of patients (11). The as-
sociation with this type of systemic disease is an indication 
of the role of the immune system in the pathophysiology 
of scleritis, but in our series this association was weak with 
most cases not presenting an underlying disease.
Previous occurrence of eye surgery or eye inflammatory 
conditions, such as occurred with a few patients in our study 
(8%), could represent an initial stimulus for the formation 
of antibodies against sclera-specific antigens (22). Surgically-
induced exposure of eye antigens under an inflammatory 
environment may trigger the sensitization of both humoral 
and cellular immunity (23). The reduction of reports of this 
type of scleritis in the era of phacoemulsification, as op-
posed to extracapsular extractions, is good evidence of this. 
The observation that scleritis may occur even several years 
after the surgery suggests that immune disorder triggered 
by the original autoimmunization stimulus may take years 
to become clinically manifest (24).
The association between autoantibodies and scleritis is 
poorly documented in the literature. In the present report 
it is noteworthy that one of the patients with scleritis pre-
sented high rates of antinuclear factor without any other 
noticeable cause, such as systemic lupus erythematosus, 
autoimmune thyroiditis, infections, chronic use of medi-
cines, or any other systemic disease. According to Zierhut 
et al.(25), approximately 28% of patients with scleritis are 
ANA-positive. The presence of anticardiolipin antibodies, 
in patients with scleritis was previously described (6) and was 
observed in two patients of this study, although in very low 
titer. Although the anti-phospholipid antibodies are ma-
rkers of thrombogenic syndromes and are frequently found 
in systemic lupus erythematosus (26,27), they may also be 
detected in low titer and transiently in several inflam matory 
conditions and idiopathic scleritis could well represent one 
of those. Some authors argue that the presence of low titer 
anticardiolipin antibodies is a non-specific expression of 
auto-immunity with multi-systemic involvement and may 
also be found in idiopathic scleritis (11).
Antiperinuclear factor (APF) was positive in two of our 
patients. This is an interesting finding since we could find no 
other reports of this occurrence. In addition, none of these 
two patients presented any evidence of systemic rheumatic 
disease. Curiously, one the patients presented both APF and 
ANA. APF represents one of the diagnostic tools for detec-
tion of autoantibodies to citrullinated peptides, which have 
been shown to be highly specific for rheumatoid arthritis (28). 
Currently, this class of autoantibodies is considered the main 
diagnostic marker for rheumatoid arthritis. They are detected 
early in the course of the disease, even before clinical signs 
and symptoms, as observed in a study performed with blood 
donors who developed rheumatoid arthritis but who already 
presented these antibodies several years before the appearance 
of the disease. In addition, some authors show evidence that 
high titer of autoantibodies to citrullinated peptides may also 
suggest a prognostic factor  (29-30). The significance of APF in 
our series of patients with idiopathic scleritis is not clear at the 
present time. However, one can not rule out the possibility 
that these patients may develop rheumatoid arthritis within 
the next years. 
With respect to traditional autoantibodies, their investi-
gation has only been recommended for scleritis patients with 
clinical evidence of systemic diseases (8). In face of the present 
results, we recommend, however, that each patient with 
idiopathic scleritis should also have a standard autoantibody 
screening, since a positive result may identify a subset of these 
patients who will eventually develop systemic manifestations.
Organ-specific autoantibodies in ophthalmology have 
been demonstrated before. The presence of specific auto-
antibodies against cornea, iris, crystalline, and some pro-
teins of the posterior segment as antigen-S and rodopsin 
have been reported, specially in the context of idiopathic 
uveitis (31,32). Our group has demonstrated the presence of 
specific antibodies against uveal extract in patients with 
non-HLA-B27 associated idiopathic uveitis (32). However, 
the literature does not report on autoantibodies in idio-
pathic scleritis. Therefore the current demonstration of 
autoantibodies directed against two polypeptides (15 kDa 
e 40 kDa) present in human sclera extract is relevant and 
raises the possibility of an organ-specific autoimmune pro-
cess. It should be mentioned that this reactivity in western 
blot corresponded to an intense fluorescence staining in 
scleral tissue, what brings credibility to both findings. 
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Similar to the inflammatory infiltrate observed in rheu-
matoid arthritis, scleritis is represented predominantly by 
a cellular infiltrate represented by macrophages and CD4 
T-lymphocytes, which usually are not observed within 
the normal sclera (24). The present study showed for the 
first time the participation of humoral immunity in this 
process. This is an interesting finding and further studies 
in a larger number of patients may shed more light into 
this immune mechanism, which may also have therapeutic 
implications.
Conflits of interest: nothing to disclose. 
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